5323312022-04-012022-06-305323312022-04-012022-06-30in-bse-fin:OtherExpenses1Member5323312022-04-012022-06-30

ItemsThatWillNotBeReclassifiedToProfitAndLoss1

5323312022-04-012022-06-30

ItemsThatWillBeReclassifiedToProfitAndLoss1

iso4217:INRiso4217:INRxbrli:shares

532331

AJANTPHARM

NOTLISTED

INE031B01049

AJANTA PHARMA LIMITED

Equity

2022-04-01

2023-03-31

2023-07-28

2022-07-20

INR

Crores

First quarter

Single segment

PHARMACEUTICAL

2022-07-28

14:00:00

2023-07-28

15:50:00

Not applicable

2022-04-01

2022-06-30

Unaudited

Consolidated

9509300000

327600000

9836900000

1950500000

365400000

488300000

1829400000

8800000

317800000

2658100000

7618300000

2218600000

455100000

17300000

472400000

1746200000

53000000

1799200000

257100000

13.63

1. The above consolidated financial results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 28 July 2022. The statutory auditors have expressed unmodified opinion. The review report has been filed with the stock exchange and is available on company website. 2. The consolidated unaudited financial results of the Company, its wholly owned subsidiaries and step-down subsidiary (“the Group”) have been prepared as per Ind AS 110 on Consolidated Financial Statements. There is no minority interest. 3. The figures for the quarter ended 31 March 2022 are the balancing figures between audited figures in respect of full financial year and the unaudited published year to date figure upto the third quarter ended 31 December 2021. 4. During the quarter 1,000 (previous year Nil) equity shares of Rs. 2 each, fully paid up, were allotted upon exercise of vested options pursuant to Share Based Incentive Plan, 2019, resulting in an increase in paid-up share capital by Rs. 2,000 (previous year Rs. Nil) and securities premium by Rs. 0.18 crores (previous year Rs. Nil). 5. Pursuant to approval given by its shareholders, the Group has during the quarter ended June 2022, issued 4,27,08,385 equity shares of Rs. 2 each as fully paid up bonus equity shares in the ratio of 1 (one) equity share for every 2 (Two) existing equity share. Accordingly, the earnings per share has been adjusted for previous periods and presented in accordance with Ind AS 33, Earnings Per Share. 6. The Group continued to take into account the possible impacts of COVID-19 in preparation of the financial statements, including but not limited to its assessment of liquidity and going concern assumption, recoverable values of its financial and non-financial assets, impact on revenues and on costs. The Group has been able to effectively manage the operations till now with appropriate safety precautions, without any significant impact of COVID-19 on the business. The Group will continue to closely monitor future economic conditions to ensure business continuity. 7. The Group operates exclusively in one reportable business segment i.e., "Pharmaceuticals". 8. The Financial Results are available on the company's website www.ajantapharma.com, www.nseindia.com and www.bseindia.com.

Other Expenses

2658100000

Items that will not to be reclassified subsequently to profit or loss

1500000

500000

Items that will be reclassified subsequently to profit or loss

52000000